



THE TRENDLINES GROUP LTD.

(Incorporated in Israel)

(Company Registration No. 513970947)

B. Braun Melsungen AG to Invest in Trendlines Medical Singapore Pte. Ltd.

The board of directors (the "**Board**") of The Trendlines Group Ltd. (the "**Company**" and together with its subsidiaries and associated companies, the "**Group**") refers to the Company's announcement dated 18 July 2016 regarding the incorporation of a wholly-owned subsidiary, Trendlines Medical Singapore Pte. Ltd. ("**Trendlines Medical Singapore**") in Singapore.

The Board wishes to announce that the Company has signed a non-binding Memorandum of Understanding (the "**MOU**") with B. Braun Melsungen AG ("**B. Braun**"), a German medical and pharmaceutical device company, which sets forth the principal terms to be included in a definitive collaboration agreement to be entered into between the Company and B. Braun in connection with their investment in, and operation of, Trendlines Medical Singapore (the "**Definitive Agreement**").

The MOU provides that, upon the execution of the Definitive Agreement, B. Braun shall subscribe for new ordinary shares in the capital of Trendlines Medical Singapore such that it will be a minority investor in Trendlines Medical Singapore.

In addition, the MOU provides that following such execution of the Definitive Agreement and subject to confirmation of funding from the Singapore Government, B. Braun and the Company (including third party investors, if any) will jointly invest in Trendlines Medical Singapore to support the development of its portfolio companies, and actively consider follow-on investment opportunities in these portfolio companies.

Subsequent to the investment by B. Braun (and third party investors, if any), the Company shall own a majority of the issued and outstanding share capital of Trendlines Medical Singapore.

B. Braun will appoint Ms. Anna Maria Braun, President of B. Braun Asia Pacific, as a member to the board of Trendlines Medical Singapore.

The Company and B. Braun shall endeavour to conclude the Definitive Agreement by no later than 30 September 2016. There is no certainty or assurance as at the date of this announcement that the Definitive Agreement will be entered as contemplated under the MOU and/or that the Singapore Government shall provide funding to Trendlines Medical Singapore.

Interest of Directors and Substantial Shareholders

None of the Company's Directors, substantial shareholders and/or any of their respective associates has any interest, direct or indirect (other than through their shareholdings in the Company), in the MOU.

Further Announcement

The Company will make further announcement(s) if and when there are any material updates to the MOU including, *inter alia*, the execution of the Definitive Agreement between the Company and B. Braun and the material terms as contained in the Definitive Agreement.

BY ORDER OF THE BOARD THE TRENDLINES GROUP LTD.

Yosef Ron,
Joint Company Secretary

8 September 2016

*The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").*

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.

For Immediate Release

Trendlines and B. Braun Enter into Memorandum of Understanding for investment in Trendlines Medical Singapore

- **Trendlines Medical Singapore will focus on the incubation and commercialization of early-stage healthcare companies with a focus on Singapore and the region**
- **B. Braun will invest in Trendlines Medical Singapore and along with Trendlines, support the development of portfolio companies, and actively consider follow-on investment opportunities in portfolio companies**
- **Ms. Anna Maria Braun, President of B. Braun Asia Pacific, will join Trendlines Medical Singapore's board of directors**
- **The first medical incubator established by an Israeli company in Singapore and Trendlines' first incubator outside of Israel**

Singapore, 8 September 2016 – The Trendlines Group Ltd. (“**Trendlines**”), an Israeli company listed on Catalist of the Singapore Exchange focused on establishing and developing innovation-based companies in the medical and agricultural fields, and B. Braun Melsungen AG (“**B. Braun**”), one of the world's leading providers of healthcare solutions with 56,000 employees in 64 countries, jointly announced today that they have entered into a Memorandum of Understanding (“**MOU**”), under which, B. Braun and Trendlines will jointly invest in Trendlines Medical Singapore Pte. Ltd. (“**Trendlines Medical Singapore**”), both parties will appoint members to Trendlines Medical Singapore's board of

directors and investment committee, and B. Braun will advise on market needs and technical and commercial matters.

The incorporation of Trendlines Medical Singapore was previously announced on the Singapore Exchange on 18 July 2016. Trendlines Medical Singapore will be a platform for the investment in and incubation of early-stage healthcare companies with a focus on Singapore and the region.

B. Braun, as a co-founder of Trendlines Medical Singapore, will support the development of the portfolio companies by providing its expertise in the medical technology field, including technological development, regulatory, medical & scientific affairs, and marketing and sales.

Mr Eric Loh has been appointed chief executive of Trendlines Medical Singapore. Mr. Loh has more than 20 years of experience in the medical device industry. Mr. Loh formerly served as senior vice-president at Biosensors International, an early-stage cardiovascular device company listed in Singapore, where he led corporate development and sales and marketing and commercialized Biosensors' products in the fast-growing Chinese market and other Asia Pacific markets. He was also involved in Biosensor's initial public offering ("IPO") on the Singapore Exchange and in merger and acquisition transactions that advanced the company.

Ms. Anna Maria Braun, a deputy member of the Management Board of B. Braun, will become a member of the board of directors of Trendlines Medical Singapore. Ms. Braun is the President of B. Braun Asia Pacific, responsible for the business of the global pharmaceutical and medical technology company in the region, including one of the group's largest manufacturing sites in the world with over 7,000 employees in Penang, Malaysia. Ms. Braun will share her healthcare industry expertise by providing advice and support to Trendlines Medical Singapore and its portfolio of companies, in areas related to B. Braun's activities.

Commenting on the establishment of Trendlines Medical Singapore, Mr. D. Todd Dollinger, Chairman and CEO of Trendlines, said, *"We announced our plan to establish an incubator in Singapore as part of our international expansion strategy at the time of the IPO on the Singapore Exchange. We are pleased that B. Braun, a strategic partner of Trendlines since our IPO, will participate in the development of the incubator and will enhance our collaboration in the global healthcare industry. The combination of Trendlines' experience in business incubation,*

B. Braun's knowledge and industry insights and financial strength, gives strong support to the launch of Trendlines Medical Singapore."

Mr. Eric Loh, CEO of Trendlines Medical Singapore, added, *"Trendlines Medical Singapore is our first incubator outside of Israel. Singapore offers a conducive environment for innovation commercialization, with a strategic location as a business hub in Asia, generation of innovative ideas from universities, research institutes and professionals in the medical field and great support from the Singapore government. By applying our business model and expertise in incubation beyond Israel, we can tap the growth opportunities in Singapore and the wider Asia-Pacific region, nurture the development of innovative technologies in the healthcare sector, and play a larger role in improving the human condition."*

Commenting on the partnership, Ms. Anna Maria Braun, director of Trendlines Medical Singapore, and President of B. Braun Asia Pacific, said, *"Asia is a strategic area of growth for B. Braun, given its dynamic and innovative environment for medical technology start-up companies. By continually sharing expertise in dialogue with our partners, B. Braun aims to protect and improve the health of people around the world. I am delighted with the forging of this partnership between B. Braun and Trendlines Medical Singapore, and look forward to the creation and advancement of innovative medical solutions to benefit customers and patients in Asia Pacific and the world."*

- The End -

Issued for and on behalf of The Trendlines Group Ltd.

By Financial PR Pte Ltd.

For more information, please contact:

Romil SINGH / Reyna MEI

romil@financialpr.com.sg / reyna@financialpr.com.sg

Tel: (65) 6438 2990, Fax: (65) 6438 0064

About B. Braun

With over 56,000 employees in 64 countries, B. Braun is one of the world's leading manufacturers of medical devices and pharmaceutical products and services. Through constructive dialogue, B. Braun develops high quality product systems and services that are both evolving and progressive - and in turn improves people's health around the world. In 2015, the group generated sales of approximately €6.13 billion.

www.bbraun.com

About The Trendlines Group Ltd.

[Trendlines](#) is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines is traded on the Singapore Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release. This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.

Issuer/Manager	THE TRENDLINES GROUP LTD.
----------------	---------------------------

Securities	THE TRENDLINES GROUP LTD. – IL0011328858 – 42T
------------	--

Stapled Security	No
------------------	----

Announcement Title	General Announcement
--------------------	----------------------

Date & Time of Broadcast	08-Sep-2016 18:10:27
--------------------------	----------------------

Status	New
--------	-----

Announcement Subtitle	Announcement and Press Release - B. Braun's Investment in Trendlines Medical Singapore
-----------------------	---

Announcement Reference	SG1609080THR3YFZ
------------------------	------------------

Submitted By (Co./Ind. Name)	Yosef Ron
------------------------------	-----------

Designation	Joint Company Secretary
-------------	-------------------------
